Valneva SE Logo

Valneva SE (INRLF)

OTC

Currency in USD
3.37
0.00 (0.00%)

Real-time Data

01:30 PM

Day's Range

3.37
3.37

52 wk Range

2.43
5.90

Overview - INRLF - Valneva SE

Key Statistics

Valuation

Enterprise Value

817.64M

P/E (Trailing)

‪68.89‬

Price / Sales (TTM)

‪4.47‬

Price / Book

‪6.95‬

EV / EBITDA

‪-7.37‬

Profitability

Gross Margin

‪4.57%‬

Profit Margin

‪-110.29%‬

Operating Margin

‪-74.91%‬

Return on Assets

‪-16.68%‬

Return on Equity

‪-117.84%‬

Ownership

Shares Outstanding

204.23M

Float

157.26M

Held by Insiders

‪10.72%‬

Held by Institutions

‪23.46%‬

Price stats

Beta

‪1.37‬

50-Day Avg

‪3.04‬

200-Day Avg

‪3.51‬

Dividends

Payout Ratio

‪0.00%‬

Shariah Compliance

Questionable Compliance

Report Date: Feb 15, 2025

Screened by Zoya using the AAOIFI methodology.

News Teaser - INRLF - Valneva SE

News & Analysis

View all news

Market Cap - INRLF - Valneva SE

Peers - INRLF - Valneva SE

Peer Comparison

Compared with companies in Biotechnology listed on OTC.

Profile Summary - INRLF - Valneva SE

About

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs. Its commercial portfolio features three key vaccines: IXIARO®, for Japanese encephalitis;…

SectorHealthcare
IndustryBiotechnology
Employees620
Full company profile

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.

Last updated:

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.